Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition. Local targets link to admitted publications; unresolved targets remain external evidence.
Rhabdomyosarcoma
10.1053/j.sempedsurg.2016.09.011 · 2016 · External reference
Rhabdomyosarcoma: review of the Children’s Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies
10.1002/pbc.24118 · 2012 · External reference
Insights into pediatric rhabdomyosarcoma research: challenges and goals
10.1002/pbc.27869 · 2019 · External reference
Roadmap for the next generation of Children’s Oncology Group rhabdomyosarcoma trials
10.1002/cncr.35457 · 2024 · External reference
NAD(+) metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus
10.1016/j.cmet.2015.05.023 · 2015 · External reference
Resurgence of serine: an often neglected but indispensable amino acid
10.1074/jbc.r112.357194 · 2012 · External reference
The NAD metabolome–a key determinant of cancer cell biology
10.1038/nrc3340 · 2012 · External reference
Beyond energy metabolism: exploiting the additional roles of NAMPT for cancer therapy
10.3389/fonc.2019.01514 · 2019 · External reference
NAPRT silencing in FH-deficient renal cell carcinoma confers therapeutic vulnerabilities via NAD+ depletion
10.1158/1541-7786.mcr-23-1003 · 2024 · External reference
NAD+ metabolism in health and disease
10.1016/j.tibs.2006.11.006 · 2007 · External reference
The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies
10.1182/blood-2008-08-173369 · 2009 · External reference
On-target effect of FK866, a nicotinamide phosphoribosyl transferase inhibitor, by apoptosis-mediated death in chronic lymphocytic leukemia cells
10.1158/1078-0432.ccr-14-0624 · 2014 · External reference
Selective cytotoxicity of the NAMPT inhibitor FK866 toward gastric cancer cells with markers of the epithelial-mesenchymal transition, due to loss of NAPRT
10.1053/j.gastro.2018.05.024 · 2018 · External reference
Dependence of tumor cell lines and patient-derived tumors on the NAD salvage pathway renders them sensitive to NAMPT inhibition with GNE-618
10.1593/neo.131304 · 2013 · External reference
Efficacy and safety of APO866 in patients with refractory or relapsed cutaneous T-cell lymphoma: a phase 2 clinical trial
10.1001/jamadermatol.2016.0401 · 2016 · External reference
The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor
10.1007/s10637-007-9083-2 · 2008 · External reference
Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data
10.1007/s00280-009-1125-3 · 2010 · External reference
Cardiotoxicity associated with nicotinamide phosphoribosyltransferase inhibitors in rodents and in rat and human-derived cells lines
10.1007/s12012-016-9387-6 · 2017 · External reference
From the cover: inhibitors of nicotinamide phosphoribosyltransferase cause retinal damage in larval zebrafish
10.1093/toxsci/kfx212 · 2018 · External reference
Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase
10.1093/toxsci/kfu268 · 2015 · External reference
EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells
10.18632/oncotarget.14976 · 2017 · External reference
Matrix screen identifies synergistic combination of PARP inhibitors and nicotinamide phosphoribosyltransferase (NAMPT) inhibitors in ewing sarcoma
10.1158/1078-0432.ccr-17-1121 · 2017 · External reference
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) with OT-82 induces DNA damage, cell death, and suppression of tumor growth in preclinical models of Ewing sarcoma
10.1038/s41389-020-00264-0 · 2020 · External reference
Nicotinic acid phosphoribosyltransferase regulates cancer cell metabolism, susceptibility to NAMPT inhibitors, and DNA repair
10.1158/0008-5472.can-16-3079 · 2017 · External reference
Inhibition of NAD+-dependent metabolic processes induces cellular necrosis and tumor regression in rhabdomyosarcoma models
10.1158/1078-0432.ccr-23-0200 · 2023 · External reference
Targeting the NAD salvage synthesis pathway as a novel therapeutic strategy for osteosarcomas with low NAPRT expression
10.3390/ijms22126273 · 2021 · External reference
Targeting DNA damage repair functions of two histone deacetylases, HDAC8 and SIRT6, sensitizes acute myeloid leukemia to NAMPT inhibition
10.1158/1078-0432.ccr-20-3724 · 2021 · External reference
NAD synthesis pathway interference is a viable therapeutic strategy for chondrosarcoma
10.1158/1541-7786.mcr-17-0293 · 2017 · External reference
PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma
10.1038/s41467-019-11732-6 · 2019 · External reference
The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors
10.1128/mcb.00112-09 · 2009 · External reference
Extreme vulnerability of IDH1 mutant cancers to NAD+ depletion
10.1016/j.ccell.2015.11.006 · 2015 · External reference
A method to culture human alveolar rhabdomyosarcoma cell lines as rhabdospheres demonstrates an enrichment in stemness and Notch signaling
2021 · External reference
CD133 positive embryonal rhabdomyosarcoma stem-like cell population is enriched in rhabdospheres
10.1371/journal.pone.0019506 · 2011 · External reference
FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis
2003 · External reference
OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis
10.1038/s41375-019-0692-5 · 2020 · External reference
Relationship of DNA methylation to mutational changes and transcriptional organization in fusion-positive and fusion-negative rhabdomyosarcoma
10.1002/ijc.32006 · 2019 · External reference
SWAN: subset-quantile within array normalization for illumina infinium HumanMethylation450 BeadChips
10.1186/gb-2012-13-6-r44 · 2012 · External reference
Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays
10.1093/bioinformatics/btu049 · 2014 · External reference
Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors
10.1158/2159-8290.cd-13-0639 · 2014 · External reference
Immuno-transcriptomic profiling of extracranial pediatric solid malignancies
10.1016/j.celrep.2021.110047 · 2021 · External reference
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
10.1186/1471-2105-12-323 · 2011 · External reference
STAR: ultrafast universal RNA-seq aligner
10.1093/bioinformatics/bts635 · 2013 · External reference
edgeR: a Bioconductor package for differential expression analysis of digital gene expression data
10.1093/bioinformatics/btp616 · 2010 · External reference
Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls
10.3389/fonc.2013.00183 · 2013 · External reference
Nicotinamide phosphoribosyltransferase inhibitors selectively induce apoptosis of AML stem cells by disrupting lipid homeostasis
10.1016/j.stem.2021.06.004 · 2021 · External reference
Loss of NAPRT1 expression by tumor-specific promoter methylation provides a novel predictive biomarker for NAMPT inhibitors
10.1158/1078-0432.ccr-13-1186 · 2013 · External reference
Extensive regulation of nicotinate phosphoribosyltransferase (NAPRT) expression in human tissues and tumors
10.18632/oncotarget.6538 · 2016 · External reference
Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models
10.1593/neo.131718 · 2013 · External reference
Discovery of a highly selective NAMPT inhibitor that demonstrates robust efficacy and improved retinal toxicity with nicotinic acid coadministration
10.1158/1535-7163.mct-16-0674 · 2017 · External reference
A simple practice guide for dose conversion between animals and human
10.4103/0976-0105.177703 · 2016 · External reference
NAD metabolic dependency in cancer is shaped by gene amplification and enhancer remodelling
10.1038/s41586-019-1150-2 · 2019 · External reference
NAD+ consumption by PARP1 in response to DNA damage triggers metabolic shift critical for damaged cell survival
10.1091/mbc.e18-10-0650 · 2019 · External reference
The alkylating chemotherapeutic temozolomide induces metabolic stress in IDH1-mutant cancers and potentiates NAD+ depletion-mediated cytotoxicity
10.1158/0008-5472.can-16-2263 · 2017 · External reference
Mechanisms of resistance to NAMPT inhibitors in cancer
2025 · External reference
